Proactive Investors - Run By Investors For Investors

Imugene granted Canadian patent for proprietary cancer vaccine

Immunotherapies are predicted to generate sales of US$36 billion by 2025.
Imugene granted Canadian patent for proprietary cancer vaccine
Immuno-oncology is a relatively new but highly promising field

Imugene (ASX:IMU) has achieved a major milestone by securing a patent for its proprietary cancer vaccine, HER-Vaxx, from the Canadian Patent Office.

The company’s shares were last trading 13% higher intra-day, at A$0.017.

HER-Vaxx is a next generation cancer immunotherapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.

Immuno-oncology is a relatively new but highly promising field that uses the method of activating a patient's immune system against tumour growth.

Imugene is currently enrolling gastric cancer patients at eight key cancer hospital sites in Asia, including Hong Kong, Thailand and Taiwan.

HER-Vaxx works by targeting the same receptor (and additional receptors) as Herceptin and Perjeta, two of the leading antibody drugs on market, with annual sales of US$8.2 billion.

Current immunotherapies are predicted to generate sales of US$36 billion by 2025 but costs remain prohibitive for patients.

The mechanism of action for HER-Vaxx may help generate improved efficacy over existing treatments and at a lower cost.

Gastric cancer is a leading cause of cancer death worldwide, representing 10.1% of male cases, with the incidence of gastric cancer substantially higher in Asia.

Imugene had raised circa A$3 million as part of an option plan which expired on 31 March 2017, at a price of A$0.015 per share.

View full IMU profile View Profile

Imugene Ltd Timeline

Newswire
October 19 2016

Related Articles

parsortix
January 03 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
1543827262_757z468_1542845960_Paradigm-cover.JPG
December 03 2018
The readout of clinical trials is expected this month.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use